3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Neutropenia
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Interventions
fludarabine
30
Specimen Handling
28
Cyclophosphamide
27
Azacitidine
23
venetoclax
22
fludarabine phosphate
22
Biopsy
22
ruxolitinib
18
Whole-Body Irradiation
17
Cytarabine
17
Mycophenolic Acid
16
Busulfan
16
asciminib
15
Tacrolimus
15
Melphalan
14
Injections
12
Decitabine
12
decitabine and cedazuridine drug combination
11
X-Rays
11
Magnetic Resonance Spectroscopy
11
Stem Cell Transplantation
10
Granulocyte Colony-Stimulating Factor
10
Sirolimus
9
Peripheral Blood Stem Cell Transplantation
9
Cyclosporine
9
Thiotepa
8
Filgrastim
8
nilotinib
7
Imatinib Mesylate
7
Phantoms, Imaging
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Levofloxacin
×
Myeloid
×
90 days
×
Clear all
NCT07528417
2026-04-22
MYELO-CAN:ABX
University of Manitoba
Phase 2
Not yet recruiting
75 enrolled